205 related articles for article (PubMed ID: 11825540)
1. Use of ursodeoxycholic acid in patients with liver disease.
Angulo P
Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
[TBL] [Abstract][Full Text] [Related]
2. Bile Acids as Signaling Molecules: Role of Ursodeoxycholic Acid in Cholestatic Liver Disease.
Cifuentes-Silva E; Cabello-Verrugio C
Curr Protein Pept Sci; 2024; 25(3):206-214. PubMed ID: 37594109
[TBL] [Abstract][Full Text] [Related]
3. UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis.
Bessone F; Hillotte GL; Ahumada N; Jaureguizahar F; Medeot AC; Roma MG
Semin Liver Dis; 2024 Feb; 44(1):1-22. PubMed ID: 38378025
[TBL] [Abstract][Full Text] [Related]
4. Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients.
Thompson PA; Wertheim BC; Roe DJ; Ashbeck EL; Jacobs ET; Lance P; Martínez ME; Alberts DS
Cancer Prev Res (Phila); 2009 Dec; 2(12):1023-30. PubMed ID: 19952360
[TBL] [Abstract][Full Text] [Related]
5. Enzymatic Synthesis of New Acetoacetate-Ursodeoxycholic Acid Hybrids as Potential Therapeutic Agents and Useful Synthetic Scaffolds as Well.
Venturi V; Marchesi E; Perrone D; Costa V; Catani M; Aprile S; Lerin LA; Zappaterra F; Giovannini PP; Preti L
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542941
[TBL] [Abstract][Full Text] [Related]
6. Bile acids in treatment of ocular disease.
Boatright JH; Nickerson JM; Moring AG; Pardue MT
J Ocul Biol Dis Infor; 2009 Sep; 2(3):149-159. PubMed ID: 20046852
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G; Beuers U
Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
[TBL] [Abstract][Full Text] [Related]
8. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.
Colombo C; Setchell KD; Podda M; Crosignani A; Roda A; Curcio L; Ronchi M; Giunta A
J Pediatr; 1990 Sep; 117(3):482-9. PubMed ID: 2391610
[TBL] [Abstract][Full Text] [Related]
9. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.
Ersöz G; Günşar F; Karasu Z; Akay S; Batur Y; Akarca US
Turk J Gastroenterol; 2005 Sep; 16(3):124-8. PubMed ID: 16245220
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients.
Marschall HU; Wagner M; Zollner G; Fickert P; Lackner C; Thorell A; Trauner M
Dig Dis; 2011; 29(1):117-8. PubMed ID: 21691117
[TBL] [Abstract][Full Text] [Related]
11. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review.
Xiang Z; Chen YP; Ma KF; Ye YF; Zheng L; Yang YD; Li YM; Jin X
BMC Gastroenterol; 2013 Sep; 13():140. PubMed ID: 24053454
[TBL] [Abstract][Full Text] [Related]
12. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
Beuers U
Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
[TBL] [Abstract][Full Text] [Related]
13. New therapeutical indications of ursodeoxycholic acid.
Copaci I; Micu L; Iliescu L; Voiculescu M
Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
[TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo.
Palma J; Reyes H; Ribalta J; Hernández I; Sandoval L; Almuna R; Liepins J; Lira F; Sedano M; Silva O; Tohá D; Silva JJ
J Hepatol; 1997 Dec; 27(6):1022-8. PubMed ID: 9453428
[TBL] [Abstract][Full Text] [Related]
15. [Use of ursodeoxycholic acid combined with silymarin in the treatment of chronic ethyl-toxic hepatopathy].
Bettini R; Gorini M
Clin Ter; 2002; 153(5):305-7. PubMed ID: 12510413
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones.
Tint GS; Salen G; Colalillo A; Graber D; Verga D; Speck J; Shefer S
Ann Intern Med; 1982 Sep; 97(3):351-6. PubMed ID: 7051912
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid (UDCA) in the treatment of chronic cholestatic diseases.
Calmus Y; Poupon R
Biochimie; 1991 Oct; 73(10):1335-8. PubMed ID: 1782227
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
[TBL] [Abstract][Full Text] [Related]
20. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
